Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

everolimus 5 MG Tablet for Oral Suspension [Afinitor]

Known as: Afinitor Disperz 5 MG Tablet for Oral Suspension, EVEROLIMUS 5 mg ORAL TABLET, FOR SUSPENSION [Afinitor Disperz] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
BACKGROUND Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 2
Is this relevant?
2016
2016
Recent therapy options of gastro- intestinal neuroendocrine tumours. Neuroen- docrine tumors (NET) of gastroenteropancreatic (GEP… Expand
Is this relevant?
2016
2016
BackgroundmTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Everolimus (RAD001, Afinitor®) is an oral, selective mTOR inhibitor recently approved by the US-FDA in combination with… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2013
Review
2013
Oral everolimus (Afinitor®) in combination with exemestane is indicated for the treatment of hormone receptor-positive, human… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2012
2012
The FDA approved a dissolvable form of everolimus (Afinitor Disperz) for the treatment of children with subependymal giant cell… Expand
Is this relevant?
2012
2012
In Austria, about 24% of women with initially diagnosed breast cancer (BC) have locally advanced and about 5% have metastatic… Expand
Is this relevant?
2009
2009
2009
The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the… Expand
Is this relevant?